The glutaminase inhibitor CB-839 (Telaglenastat) enhances the anti-melanoma activity of T cell mediated immunotherapies.

Immune checkpoint inhibitors and adoptive tumor-infiltrating lymphocyte (TIL) therapies have profoundly improved the survival of melanoma patients. However, a majority of patients do not respond to these agents, and many responders experience disease relapse. While numerous innovative treatments are...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Cancer Ther
Asıl Yazarlar: Varghese, Sruthy, Pramanik, Snigdha, Williams, Leila J., Hodges, Hannah R., Hudgens, Courtney W., Fischer, Grant M., Luo, Catherine K., Knighton, Barbara, Tan, Lin, Lorenzi, Philip L., Mackinnon, Andrew L., McQuade, Jennifer L., Hailemichael, Yared, Roszik, Jason, Peng, Weiyi, Vashisht Gopal, Y. N.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7933078/
https://ncbi.nlm.nih.gov/pubmed/33361272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0430
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller